Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor.
about
Olomoucine II, but not purvalanol A, is transported by breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1)Mitogen-activated protein kinase kinase 1-dependent Golgi unlinking occurs in G2 phase and promotes the G2/M cell cycle transition.Inhibition of post-transcriptional RNA processing by CDK inhibitors and its implication in anti-viral therapy.Transient inhibition of cell proliferation does not compromise self-renewal of mouse embryonic stem cellsCyclin-dependent kinase inhibitors closer to market launch?Characterization of a Pyrazolo[4,3-d]pyrimidine Inhibitor of Cyclin-Dependent Kinases 2 and 5 and Aurora A With Pro-Apoptotic and Anti-Angiogenic Activity In Vitro.Synthesis and pharmacophore modelling of 2,6,9-trisubstituted purine derivatives and their potential role as apoptosis-inducing agents in cancer cell lines.Human embryonic stem cells suffer from centrosomal amplification.Screening and identification of small molecule inhibitors of ErbB2-induced invasion.2-(1-Adamant-yl)-1-{4-[(2-chloro-9-isopropyl-9H-purin-6-yl)amino-meth-yl]phen-yl}ethanone.The inhibitor of cyclin-dependent kinases, olomoucine II, exhibits potent antiviral properties.Placental passage of olomoucine II, but not purvalanol A, is affected by p-glycoprotein (ABCB1), breast cancer resistance protein (ABCG2) and multidrug resistance-associated proteins (ABCCs).Mapping the 3D structures of small molecule binding sites.
P2860
Q28534229-49A509F3-9065-49C7-90D8-F4D3944DBD58Q30478912-C7D30A2A-27BD-413B-8155-E2F7FBD480FEQ35106892-9C4C4BFC-1F10-476E-8806-3A589C3D8349Q36129237-E661D2F2-434B-4C01-9916-CB9A761A95F5Q38100203-BDF5B9E7-63B2-4F7B-8274-20F6B8DC28EEQ38850709-C14A169B-1A71-49DD-B5A1-7AE86F8A1FD2Q38885840-44341269-DFCD-4222-9186-8C9684A22A51Q39641991-361DDE1F-CBF0-4AC6-B0A7-2D535E802EF0Q41135384-735E8C2E-23C3-4FFF-892D-6B07CC89DE4CQ41860006-005B8223-0BE9-45DB-95DE-CD4B93A659EDQ42122796-299D14D2-0CE5-41DA-8564-4BFFD232A638Q53818047-A8617277-8DF8-417F-BD70-CA104FADC8A8Q54572862-A9B580C7-BEAE-4177-AEA5-1EA3F3855DB1
P2860
Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Antiproliferative activity of ...... in-dependent kinase inhibitor.
@en
type
label
Antiproliferative activity of ...... in-dependent kinase inhibitor.
@en
prefLabel
Antiproliferative activity of ...... in-dependent kinase inhibitor.
@en
P2093
P50
P1476
Antiproliferative activity of ...... lin-dependent kinase inhibitor
@en
P2093
P2888
P304
P356
10.1007/S00018-005-5185-1
P577
2005-08-01T00:00:00Z